Jasveen Batra
Family Medicine · Wethersfield, CTNPI 1497218986
Payments from drug & device makers
Across 242 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$744
- GSK$595
- Lilly USA, LLC$553
- AbbVie$306
- Novo Nordisk$265
- Pfizer$232
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,660100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $744 |
| GSK | 37 | $595 |
| Lilly USA, LLC | 28 | $553 |
| AbbVie | 25 | $306 |
| Novo Nordisk | 12 | $265 |
| Pfizer | 14 | $232 |
| Astellas Pharma US Inc | 8 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $213 |
| Exact Sciences | 8 | $178 |
| Boehringer Ingelheim | 8 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $145 |
| Otsuka America Pharmaceutical, Inc. | 4 | $104 |
| Sumitomo Pharma America, Inc. | 4 | $102 |
| Phathom Pharmaceuticals, Inc. | 2 | $80 |
| E.r. Squibb & Sons, L.L.C. | 5 | $77 |
| Merck | 4 | $76 |
| Abbott | 3 | $71 |
| Lundbeck LLC | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Corcept Therapeutics | 3 | $59 |
| Ardelyx, Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Seqirus USA Inc | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Viatris Specialty LLC | 2 | $39 |
| Almatica Pharma LLC | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$4,669 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $83,160 |
| MounjaroTirzepatide | 35 | $45,576 |
| JanuviaSitagliptin Phosphate | 28 | $44,934 |
| FarxigaDapagliflozin Propanediol | 19 | $31,211 |
| EliquisApixaban | 32 | $29,250 |
| OzempicSemaglutide | 15 | $15,373 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,111 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $11,210 |
| XareltoRivaroxaban | 14 | $7,411 |
| GemtesaVibegron | 14 | $6,394 |
| TradjentaLinagliptin | 11 | $6,188 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,482 |
| SynthroidLevothyroxine Sodium | 23 | $1,996 |
| Atorvastatin Calcium | 267 | $1,972 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 15 | $1,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $164 | $89,34887 claims |
| MerckJanuvia, Janumet | $76 | $56,14341 claims |
| Lilly USA, LLCMounjaro | $553 | $45,57635 claims |
| AstraZenecaFarxiga | $744 | $31,21119 claims |
| PfizerEliquis | $232 | $29,25032 claims |
| Novo NordiskOzempic | $265 | $15,37315 claims |
| GSKTrelegy Ellipta | $595 | $13,11120 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $102 | $6,39414 claims |
| AbbVieSynthroid | $306 | $1,99623 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $1,339113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Wethersfield
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
- Helar CamposNew London$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.